|
Staufosporine derivatives as inhibitors of receptor tyrosine kinase flt3 activity |
|
![]()
IPC classes for russian patent Staufosporine derivatives as inhibitors of receptor tyrosine kinase flt3 activity (RU 2337692):
Method for accompanying treatment of lymphoblast leucosis / 2320367
Method involves the complex using symptomatic, antibacterial, general tonic agents and nonspecific immunomodulating therapy. For this aim, lysozyme hydrochloride powder is given orally in the daily dose 500-1800 mg, 2 times per a day, every day for 20-30 days in combination with dosing sodium nucleinate in the daily dose 100-1500 mg, 2 times per a day, for 20-30 days by oral or sublingual route, and lactulose given orally in the dose 2.5-5 ml, 1-2 times per a day, every day for 10-30 days. Lysozyme hydrochloride is given 0.5-1 h before eating, sodium nucleinate is given after intake of lysozyme hydrochloride directly and lactulose is given 20-30 min before eating, or before eating immediately, or in 3-4 h after intake of lysozyme hydrochloride and sodium nucleinate. Method provides the complex correction of nonspecific resistance of body in patients suffering from leukosis and involving maintenance of immune homeostasis, plasma proteolysis, intestine microecology and reparative processes and improved tolerance of scheduled polychemotherapy.
Method for chemotherapy of acute leukosis / 2318519
Invention relates to a method for chemotherapy of acute leucosis. Method involves isolation of blast cells and interphase cells from marrow puncture sample leukocyte fraction of blood of a patient subjected for chemotherapy. Then cells are deposited by centrifugation in medium 199 and their concentration is brought about to the level (2-3) x 106 cells/ml. Then isolated cells are incubated with each chemotherapeutic drug chosen from the following group: dexamethasone, cyclophosphanum, vincristine, teniposide, etoposide, citarabinum that are diluted preliminary with isotonic solution to the concentration 1:1000. Then cells treated with chemotherapeutic drugs are centrifuged repeatedly in medium 199 followed by carrying out the annexin test. In the schedule treatment drugs that showed the maximal percent of cells apoptosis are used. Method provides maximal decreasing adverse and toxic effects of chemotherapeutic drugs and to enhance apoptosis of tumor cells based on individual selection of chemotherapeutic drugs for a patient, to prolong remission period and to exclude using additional curative effects.
![]()
Invention relates to amide derivative represented by the following formula [1]:
![]()
Invention proposes a pharmaceutical composition that contains compounds of chlorogenic acid isolated from Piper betel leaves extract or from any other part of plant Piper betel and a pharmaceutically acceptable excipient. Invention provides enhanced effectiveness of treatment of such diseases as acute and chronic myeloid leucosis and lymphoid leucosis and absence of its effect on normal cells. Invention can be used in treatment of patients suffering from acute and chronic myeloid and lymphoid leucosis.
![]()
Invention relates to compound comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridine-4-amine or pharmaceutically acceptable salt of this compound and pharmaceutical composition used for stimulation of biosynthesis of cytokine based on abovementioned compound Also, invention claims a method for stimulation of biosynthesis of cytokines in animal body involving administration in animal body of above described compound or its salt. Invention provides preparing a novel compound possessing useful biological properties.
![]()
Invention relates to osteogenic growth oligopeptides used as stimulators of hemopoiesis. Invention proposes using an oligopeptide of molecular mass in the range from 200 to 1000 Da, comprising one of the following sequence: Tyr-Gly-Phe-Gly-Gly, Met-Tyr-Gly-Phe-Gly-Gly used in preparing a pharmaceutical composition and enhancing mobilization of hemopoietic stem cells from many differentiation line into peripheral blood, in particular, CD34-positive hemopoietic stem cells. Advantage of the invention involves expanding field in using oligopeptides used in stimulation of hemopoiesis.
![]()
Invention characterizes compositions, their employment, and embodiments of a method of treatment of B-cellular lymphomas, leucosis, and other malignant tumors CD40+. Principal active therapeutical agent is anti-CD40L antibody or another CD40L antagonist inhibiting CD40-CD40L intermediate. In combination or composition with indicated CD40L antagonist any one or several of the following components can be additionally used: anti-CD20 antibody, a chemotherapeutical agent or a combination thereof, and radiotherapy.
![]()
Invention relates to compounds of the formula (I)
![]()
Invention relates to a new compound of the formula (I):
![]()
Invention relates to new inhibitors of farnesyltransferase of the formula (I):
![]()
Compound of formula [I]:
![]() Invention relates to the new compounds presented by the following formula (I), or to the pharmaceutically acceptable salts:
![]()
Claim describes benzoxazepinone derivatives of formula
![]()
Invention relates to novel azaheterocycles of the general formula (I):
![]()
Drugs contain H-SGK kinase having lysine substituted by arginine in position 127.
![]()
Invention relates to derivatives of general formula I
![]()
Invention relates to derivatives of benzoxazepine and describes derivative of benzoxazepine of the general formula (I):
![]()
Invention proposes a method for inhibition of chorionic neovascularization. Method involves irradiation of undesirable novel vascular reticulum in combination with photosensitive agent (porphyrine) and an anti-angiogenic agent taken among antagonist of phospholipase A2, inhibitor of complex kappa B, inhibitor of the growth hormone, inhibitor of insulin-like growth factor-1, inhibitor of cyclooxygenase II, inhibitor of protein kinase C (stautosporin PKC 412) and inhibitor of angiotensin II. The claimed combined treatment provides potentiation of effect of adjunctive photodynamic therapy in combination with enhanced safety.
![]()
Invention relates to a spontaneously dispersing composition comprising N-benzoylstaurosporin, a hydrophilic component, a lipophilic component and a surface-active substance taken in the definite ratio of components. Also, invention relates to a method for treatment of the patient needing administration of N-benzoylstautosporin as a component of the spontaneously dispersing composition. The composition possesses the enhanced level of biological availability or diminished variability of the biological availability levels and effectiveness.
![]()
The invention relates to new derivatives of K-a (a derivative of indolocarbazole), which are represented by the General formula 1, as well as to a method for improving the functioning and/or increase the survival of cholinergic neurons and the way to improve cell survival at risk of death because of the compounds of formula 1 inhibit production of interleukin-2 and have immunosuppressive activity
![]()
Invention relates to a spontaneously dispersing composition comprising N-benzoylstaurosporin, a hydrophilic component, a lipophilic component and a surface-active substance taken in the definite ratio of components. Also, invention relates to a method for treatment of the patient needing administration of N-benzoylstautosporin as a component of the spontaneously dispersing composition. The composition possesses the enhanced level of biological availability or diminished variability of the biological availability levels and effectiveness.
|
FIELD: medicine; pharmacology. SUBSTANCE: invention concerns application of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9N-diindolo [1,2,3-gh:3', 2', 1'-lm] pyrrolo[3,4-j][1,7]benzodiasonine-11-yl]-N-methylbenzamide of formula EFFECT: high efficiency of treatment. 6 cl, 1 tbl, 2 ex
The text descriptions are given in facsimile form. 1. The use of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,N-vindaloo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazepin-11-yl]-N-methylbenzamide formula (VII) or its salt to obtain a pharmaceutical composition intended for the treatment of diseases associated with uncontrolled activity of the receptor tyrosine kinase FLT3. 2. The use according to claim 1 for the treatment of leukemias and myelodysplastic syndromes. 3. The use according to claim 1 for the treatment of acute myeloid leukemia and myelodysplastic the x syndromes at high risk. 4. Pharmaceutical preparation for the treatment of leukemia, including N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,N-vindaloo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazepin-11-yl]-N-methylbenzamide formula (VII) in an effective amount. 5. The product, including packaging material and N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,N-vindaloo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazepin-11-yl]-N-methylbenzamide formula (VII) according to claim 1 or its pharmaceutically acceptable salts contained in the specified packaging material, and specified packaging material includes label instructions, in which it is reported that the compound of formula (VII) or its pharmaceutically acceptable salt should be introduced mammals suffering from diseases associated with uncontrolled activity of the receptor tyrosine kinase FLT3, in the amount of from 220 to 230 mg special treatment regimen for inhibiting the development of diseases associated with uncontrolled activity of the receptor tyrosine kinase FLT3. 6. The product according to claim 5, where the compound of formula VII is administered three times daily at a total dose of from 220 to 230 mg, and preferably at a dose of from 70 to 80 mg every introduction, for the treatment of leukemia, especially acute myeloid leukemia and myelodysplastic syndromes at high risk. Priority items: 30.10.200 according to claims 1 to 4; 29.10.2002 on pp.5 and 6.
|
© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English. |